瑞银:升威高股份目标价至7.4港元 维持中国医疗科技板块首选股

新浪港股
27 Mar
热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易
客户端

  瑞银发布研报称,将威高股份(01066)今明两年收入预测下调,各年每股盈测则分别升2%及降1%,同时将公司预测范围内年度派息率预测提高至50%。该行指,将其目标价由7港元上调至7.4港元,维持中国医疗科技板块首选股之一,重申其评级为“买入”。

  该行指,威高股份去年收入同比跌1.1%至130.9亿元人民币,低于该行及市场预期,纯利同比升3.2%至20.7亿元人民币,胜于该行预期,惟逊市场预期。集团提供今年收入达10%至15%增长指引,料今年派息率达50%。该行认为,即使今年收入预测看似乐观,料股东回报呈显著改善将成为股价上涨的关键催化剂。

海量资讯、精准解读,尽在新浪财经APP

责任编辑:史丽君

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10